Sugi Predict

Sugi Predict / Targets / PTPRC

PTPRC

Receptor-type tyrosine-protein phosphatase C · P08575 · PTPRC on Sugi Atlas →

54,369 patent compounds predicted against PTPRC, 30,784 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
1,2-Naphthoquinone 1,2-Naphthoquinone (SCHEMBL173316) 1.00 8/20
1,2-Naphthoquinone 1,2-Naphthoquinone (SCHEMBL203171) 0.74 8/20
SCHEMBL57813 SCHEMBL57813 0.55 6/20
9,10-Phenanthrenequinone 9,10-Phenanthrenequinone (SCHEMBL43050) 1.00 5/20
SCHEMBL181722 SCHEMBL181722 0.55 5/20
SCHEMBL142991 SCHEMBL142991 0.55 5/20
SCHEMBL146910 SCHEMBL146910 0.53 5/20
SCHEMBL18844 SCHEMBL18844 0.52 5/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL12040) 0.52 5/20
SCHEMBL142992 SCHEMBL142992 0.51 5/20
SCHEMBL133450 SCHEMBL133450 0.45 5/20
SCHEMBL133451 SCHEMBL133451 0.43 5/20
SCHEMBL40960 SCHEMBL40960 0.87 4/20
SCHEMBL292030 SCHEMBL292030 0.70 4/20
2-Bromo-1,4-Naphthoquinone 2-Bromo-1,4-Naphthoquinone (SCHEMBL312893) 0.68 4/20
SCHEMBL43327 SCHEMBL43327 0.63 4/20
SCHEMBL159819 SCHEMBL159819 0.60 4/20
SCHEMBL143100 SCHEMBL143100 0.57 4/20
SCHEMBL19852 SCHEMBL19852 0.55 4/20
SCHEMBL79475 SCHEMBL79475 0.52 4/20

Clinical trials — most relevant to PTPRC by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance PHASE4UNKNOWN
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia PHASE3RECRUITING
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF PHASE3COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation PHASE2UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study) PHASE1/PHASE2WITHDRAWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease PHASE2COMPLETED
Cyclosporine For The Treatment Of COVID-19(+) PHASE2COMPLETED
Imatinib in Dermatofibrosarcoma Protuberans (DFSP) PHASE1/PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure nanUNKNOWN
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation nanRECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes nanRECRUITING
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients. nanCOMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Ruxolitinib in Patients With Myelofibrosis nanUNKNOWN
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4) Gene Single-nucleotide Polymorphism in Primary Immune Thrombocytopenic Purpura in Children nanNOT_YET_RECRUITING
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s) nanNOT_YET_RECRUITING
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment nanNOT_YET_RECRUITING
Dynamic Changes in the Levels of sCD62L and SPARC in Chronic Myeloid Leukemia Patients During Imatinib Treatment nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PTPRC binder may also engage these)

ProteinNameSimilarity
P04157 — 1.000 P04157 →
P06800 — 0.995 P06800 →
P16620 — 0.989 P16620 →
Q93105 — 0.987 Q93105 →
Q91909 — 0.987 Q91909 →
P43481 — 0.987 P43481 →
P26619 — 0.987 P26619 →
Q28317 — 0.987 Q28317 →
PTPRM Receptor-type tyrosine-protein phosphatase mu 0.987 landscape →
Q28889 — 0.987 Q28889 →
Q2HWD6 — 0.987 Q2HWD6 →
Q9IBD8 — 0.987 Q9IBD8 →
Q08156 — 0.987 Q08156 →
Q76II0 — 0.986 Q76II0 →
O18016 — 0.986 O18016 →
PTPRO Receptor-type tyrosine-protein phosphatase O 0.986 landscape →
P05532 — 0.985 P05532 →
Q8AXC7 — 0.985 Q8AXC7 →
D2IYS2 — 0.984 D2IYS2 →
Q8JFR5 — 0.984 Q8JFR5 →
Q8UVR8 — 0.984 Q8UVR8 →
P52583 — 0.984 P52583 →
Q96PD2 — 0.984 Q96PD2 →
PTPRR Receptor-type tyrosine-protein phosphatase R 0.984 landscape →
PTPRJ Receptor-type tyrosine-protein phosphatase eta 0.984 landscape →
Q5GIT4 — 0.984 Q5GIT4 →
Q9NA64 — 0.984 Q9NA64 →
P45442 — 0.983 P45442 →
O57254 — 0.983 O57254 →
Q9VWE0 — 0.983 Q9VWE0 →